UBS lowered the firm’s price target on Quest Diagnostics (DGX) to $175 from $176 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics introduces testing for Oropouche virus
- Quest Diagnostics: Strategic Positioning and Growth Potential Amid Reimbursement Challenges
- Quest Diagnostics to develop multi-cancer blood test with MD Anderson Center
- Quest Diagnostics management to meet with Oppenheimer
- Quest Diagnostics: Strong Growth Prospects and Strategic Initiatives Drive Buy Rating